| Name | Title | Contact Details |
|---|
Patterson Medical is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tykes & Teens was established in 1996 with the goal of strengthening local families by ensuring that all children have access to high quality counseling and mental health services, regardless of financial status. The agency provides a comprehensive range of programming in Martin, St. Lucie, Indian River and Okeechobee counties.
In 2016, OmniGuide Surgical and Domain Surgical were merged, creating an organization focused on providing better outcomes and a safer, more seamless surgical experience. Today, OmniGuide Surgical`s Enhanced Safety Flexible CO2 Laser Fibers and Domain Surgical`s FMX Ferromagnetic Technology are used in the most challenging surgical procedures throughout the world, safely delivering energy resulting in the preservation of healthy tissue. OmniGuide Surgical, based in Lexington, MA, USA, is the leader in flexible fiber CO2 laser technology; providing products that enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, located in Salt Lake City, UT, USA, provides a patented ferromagnetic technology designed to provide safety and predictability in select surgical procedures that require cutting, coagulating and sealing tissue.
Medafor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.